These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 29265182)

  • 1. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis.
    Shah NN; Szabo A; Huntington SF; Epperla N; Reddy N; Ganguly S; Vose J; Obiozor C; Faruqi F; Kovach AE; Costa LJ; Xavier AC; Okal R; Kanate AS; Ghosh N; Kharfan-Dabaja MA; Strelec L; Hamadani M; Fenske TS; Calzada O; Cohen JB; Chavez J; Svoboda J
    Br J Haematol; 2018 Feb; 180(4):534-544. PubMed ID: 29265182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.
    Dunleavy K; Pittaluga S; Maeda LS; Advani R; Chen CC; Hessler J; Steinberg SM; Grant C; Wright G; Varma G; Staudt LM; Jaffe ES; Wilson WH
    N Engl J Med; 2013 Apr; 368(15):1408-16. PubMed ID: 23574119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results.
    Tobinai K; Ogura M; Itoh K; Kinoshita T; Hotta T; Watanabe T; Morishima Y; Igarashi T; Terauchi T; Ohashi Y;
    Cancer Sci; 2010 Dec; 101(12):2579-85. PubMed ID: 20942866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful Treatment of Primary Mediastinal Large B-cell Lymphoma with DA-EPOCH-Rituximab Therapy in a Transgender Woman.
    Nakao S; Tanaka S; Abe K; Komiyama T; Sugiura Y; Nakaseko C; Shimizu N
    Intern Med; 2024 Jul; 63(13):1923-1927. PubMed ID: 37981304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective cohort study describing chemotherapy-induced peripheral neuropathy in Non-Hodgkin lymphoma patients treated with EPOCH ± R: does HIV status matter?
    McNally GA; Aossey CM; Wiczer T; Sinnott LT; Lustberg M; Baiocchi RA; Lustberg M
    Leuk Lymphoma; 2024 Aug; 65(8):1110-1116. PubMed ID: 38648546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial.
    Chamuleau MED; Stenner F; Chitu DA; Novak U; Minnema MC; Geerts P; Stevens WBC; Zenz T; van Imhoff GW; Wu KL; Demandt AMP; Kersten MJ; Terpstra WE; Tick LW; Deeren D; Van Den Neste E; Gregor M; Veelken H; Böhmer LH; Caspar CB; Mutsaers P; Refos JM; Sewsaran R; Fu L; Seefat RL; Uyl-de Groot CA; Dirnhofer S; Van Den Brand M; de Jong D; Nijland M; Lugtenburg P
    Lancet Haematol; 2023 Dec; 10(12):e966-e975. PubMed ID: 37922925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venetoclax plus dose-adjusted R-EPOCH (VR-DA-EPOCH) or G-EPOCH bridging to subsequent cellular therapy for the patients with transformed lymphoma a single center clinical experience.
    Qin S; Jiang R; Dai L; Miao Y; Sha Y; Qiu T; Ding C; Wang Z; Shi C; Xia Y; Fan L; Xu W; Li J; Zhu H
    Ann Hematol; 2024 May; 103(5):1635-1642. PubMed ID: 38246951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075).
    Ramos JC; Sparano JA; Rudek MA; Moore PC; Cesarman E; Reid EG; Henry D; Ratner L; Aboulafia D; Lee JY; Ambinder RF; Mitsuyasu R; Noy A
    Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):180-190.e2. PubMed ID: 29426719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL: A Phase 1 Dose-Escalation Trial.
    Kopmar NE; Quach K; Gooley TA; Martino CH; Cherian S; Percival MM; Halpern AB; Ghiuzeli CM; Oehler VG; Abkowitz JL; Walter RB; Cassaday RD
    JAMA Oncol; 2024 Jul; 10(7):961-965. PubMed ID: 38722664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolated central nervous system relapse in two adolescents with primary mediastinal large B-cell lymphoma after treatment with R-DA-EPOCH.
    Gullickson C; Kersun L; Reilly A; Seif A; Chehab L
    Pediatr Blood Cancer; 2024 Aug; 71(8):e31065. PubMed ID: 38721853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients.
    Barta SK; Xue X; Wang D; Tamari R; Lee JY; Mounier N; Kaplan LD; Ribera JM; Spina M; Tirelli U; Weiss R; Galicier L; Boue F; Wilson WH; Wyen C; Oriol A; Navarro JT; Dunleavy K; Little RF; Ratner L; Garcia O; Morgades M; Remick SC; Noy A; Sparano JA
    Blood; 2013 Nov; 122(19):3251-62. PubMed ID: 24014242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen.
    Karmali R; Galvez C; Hamadani M; Gordon L; Winter J; Ma S; Nelson V; Fenske TS; Shah NN; Jagadeesh D; Klein A; Helenowski I; Chen R; Mi X; Petrich A; Evens AM; Pro B
    Blood Adv; 2024 Apr; 8(7):1612-1620. PubMed ID: 38237077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of primary cardiac diffuse large B-cell lymphoma involving the coronary sinus with R-EPOCH: a case report and literature review.
    Rezvani A; Shah S
    Ann Hematol; 2024 Jul; 103(7):2557-2560. PubMed ID: 38748259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.
    Kim KM; Kim HC; Jeon KN; Kim HG; Kang JH; Hahm JR; Lee GW
    Yonsei Med J; 2008 Feb; 49(1):155-8. PubMed ID: 18306483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of immune checkpoint protein expression in MYC-overexpressing aggressive B-cell non-Hodgkin lymphomas.
    Landsburg DJ; Koike A; Nasta SD; Svoboda J; Schuster SJ; Wasik MA; Caponetti GC
    Cancer Immunol Immunother; 2021 Mar; 70(3):869-874. PubMed ID: 32857184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-grade B-cell lymphoma, not otherwise specified, presenting as primary peritoneal lymphomatosis and successfully treated with dose-adjusted EPOCH-R.
    Fujimi A; Nagamachi Y; Yamauchi N; Onoyama N; Hayasaka N; Matsuno T; Koike K; Goto Y; Ihara K; Kato J; Nishisato T; Kawase H; Yano T; Kanaseki T; Sugita S; Kobune M
    J Clin Exp Hematop; 2024 Mar; 64(1):37-44. PubMed ID: 38281744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia.
    Cassaday RD; Zarling LC; Garcia KA; Sala-Torra O; Stevenson PA; Martino CH; Liu YJ; Fang M; Percival MM; Halpern AB; Becker PS; Oehler VG; Shustov AR; Cooper JP; Orozco JJ; Hendrie PC; Walter RB; Radich JP; Soma LA; Estey EH
    Leuk Lymphoma; 2023 May; 64(5):927-937. PubMed ID: 36938892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the intratumor heterogeneity in PMBL.
    Ritz O; Möller P; Ushmorov A
    Cell Cycle; 2014; 13(15):2317-8. PubMed ID: 25483178
    [No Abstract]   [Full Text] [Related]  

  • 19. Rituximab-combined anthracycline-free chemotherapy in newly diagnosed paediatric and adolescent patients with non-high-risk aggressive mature B cell lymphoma: protocol for a single-arm, open-label, multicentre, phase II study (the Japan Children's Cancer Group Multicentre Trial, JPLSG B-NHL-20).
    Sekimizu M; Fukano R; Koga Y; Mitsui T; Fujita N; Mori T; Hori D; Tanaka M; Ohki K; Iwafuchi H; Nakazawa A; Mori T; Kobayashi R; Hashimoto H; M Saito A; Kamei M;
    BMJ Open; 2024 Mar; 14(3):e080762. PubMed ID: 38508620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is dose-adjusted EPOCH-R the new standard for high-risk Burkitt lymphoma?
    Lim KJC; Filshie R
    Lancet Haematol; 2023 Dec; 10(12):e942-e943. PubMed ID: 37922924
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.